SIMIONI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.710
EU - Europa 2.554
AS - Asia 1.665
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 19
AF - Africa 11
SA - Sud America 6
Totale 29.986
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.680
CN - Cina 1.261
IT - Italia 603
FI - Finlandia 580
DE - Germania 389
SE - Svezia 384
VN - Vietnam 325
GB - Regno Unito 226
UA - Ucraina 214
IN - India 49
IE - Irlanda 44
NL - Olanda 33
FR - Francia 28
CA - Canada 21
AU - Australia 16
EU - Europa 15
ES - Italia 9
EG - Egitto 7
BE - Belgio 6
BG - Bulgaria 6
RO - Romania 6
CH - Svizzera 5
NZ - Nuova Zelanda 5
BR - Brasile 4
HK - Hong Kong 4
JP - Giappone 4
NO - Norvegia 4
TR - Turchia 4
TW - Taiwan 4
A2 - ???statistics.table.value.countryCode.A2??? 3
CZ - Repubblica Ceca 3
HN - Honduras 3
IR - Iran 3
MX - Messico 3
PH - Filippine 3
AL - Albania 2
GR - Grecia 2
IQ - Iraq 2
RS - Serbia 2
SG - Singapore 2
A1 - Anonimo 1
AT - Austria 1
BD - Bangladesh 1
BS - Bahamas 1
CL - Cile 1
CO - Colombia 1
EE - Estonia 1
HR - Croazia 1
HU - Ungheria 1
ID - Indonesia 1
IL - Israele 1
KE - Kenya 1
MK - Macedonia 1
OM - Oman 1
PA - Panama 1
PL - Polonia 1
PR - Porto Rico 1
PT - Portogallo 1
RU - Federazione Russa 1
SZ - Regno dello Swaziland 1
TN - Tunisia 1
UG - Uganda 1
Totale 29.986
Salva come PNG Salva come JPEG
Città #
Fairfield 4.626
Woodbridge 2.971
Houston 2.065
Ann Arbor 1.994
Ashburn 1.956
Chandler 1.933
Seattle 1.649
Wilmington 1.528
Cambridge 1.499
Jacksonville 953
Princeton 600
San Diego 486
Beijing 382
Medford 334
Des Moines 324
Dong Ket 322
Roxbury 250
Helsinki 248
Nanjing 219
Boardman 197
Padova 187
Hebei 81
Shenyang 81
Nanchang 78
London 63
Norwalk 53
New York 49
Jiaxing 47
Milan 44
Jinan 41
Tianjin 40
Dublin 38
Redwood City 36
Ogden 33
Guangzhou 32
Changsha 31
Falls Church 31
Los Angeles 28
Kilburn 25
Shanghai 21
Kharkiv 20
Zhengzhou 19
Chicago 18
Washington 15
Indiana 14
Nürnberg 14
Pune 14
Borås 13
Bologna 12
Chiswick 12
Rockville 12
Hangzhou 11
Hefei 11
Sydney 11
Dearborn 10
Lappeenranta 10
Mykolayiv 9
Ningbo 9
Ferentino 8
Las Vegas 8
Acton 7
Kingston 7
Kunming 7
Legnaro 7
Taizhou 7
Tappahannock 7
Genoa 6
Haikou 6
Lanzhou 6
Prescot 6
Sofia 6
Southwark 6
Taiyuan 6
Verona 6
Altavilla Vicentina 5
Belluno 5
Esslingen am Neckar 5
Muenster 5
Portland 5
Rome 5
Boston 4
Brussels 4
Dronten 4
Falkenstein 4
Gunzenhausen 4
Hounslow 4
Longare 4
Redmond 4
Taipei 4
Venice 4
Atlanta 3
Buffalo 3
Castel San Pietro Terme 3
Chiampo 3
Civitanova Marche 3
Council Bluffs 3
De Zilk 3
Detroit 3
Manchester 3
Martinsicuro 3
Totale 26.015
Salva come PNG Salva come JPEG
Nome #
miR-30c-5p regulates macrophage-mediated inflammation and pro-atherosclerosis pathways 187
Activated Platelet-Derived and Leukocyte-Derived Circulating Microparticles and the Risk of Thrombosis in Heparin-Induced Thrombocytopenia: A Role for PF4-Bearing Microparticles? 182
Dual polarization of human alveolar macrophages progressively increases with smoking and COPD severity 171
Peculiar whole blood rotation thromboelastometry (Rotem) profile in 40 sideropenic anaemia patients 167
Dynamics of circulating microparticles in obesity after weight loss 143
In vitro and in vivo effects of the carbon monoxide-releasing molecule, CORM-3, in the xenogeneic pig-to-primate context 137
Abnormal propeptide processing resulting in the presence of two abnormal species of protein C in plasma - Characterization of the dysfunctional protein C Padua(3) (Protein CR-1L/propeptide) 134
Activated protein C resistance in normal and pre-eclamptic pregnancies 133
Secondary parenchymal and vascular changes after middle cerebral artery stroke in children. 128
Circulating levels and characterization of microparticles in patients with different degrees of glucose tolerance 128
Potential role of thrombelastography in the monitoring of acquired factor VIII inhibitor hemophilia A: report on a 78-year-old woman with life-threatening bleedings. 125
null 122
Changes in plasma circulating microvesicles in patients with HCV‐related cirrhosis after treatment with direct‐acting antivirals 121
Acute oppressive chest pain in a 66-year-old woman with a recent Amplatzer device closure of patent foramen ovale 119
Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role. 119
The Coagulative Profile of Cyanotic Children Undergoing Cardiac Surgery: The Role of Whole Blood Preoperative Thromboelastometry on Postoperative Transfusion Requirement 119
Are thromboelastometric and thromboelastographic parameters associated with mortality in septic patients? A systematic review and meta-analysis 118
Microparticles as biomarkers of venous thromboembolic events 117
Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis 116
X-linked thrombophilia with a mutant factor IX (factor IX Padua). 116
The incidence of venous thromboembolism in carriers of antithrombin, protein C or protein S deficiency associated with the HR2 haplotype of factor V: a family cohort study 115
Circulating microparticles in umbilical cord blood in normal pregnancy and pregnancy with preeclampsia 113
A matrix-assisted laser desorption/ionization time-of-flight based method for screening the 1691G --> A mutation in the factor V gene 112
Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms 111
Does decreased fibrinolysis have a role to play in the development of non-neoplastic portal vein thrombosis in patients with hepatic cirrhosis? 111
Clinical Data of Neonatal Systemic Thrombosis 111
Whole blood rotation thromboelastometry (ROTEM(®)) in nine severe factor V deficient patients and evaluation of the role of intraplatelets factor V. 109
Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells 109
Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. 108
Cerebral sinovenous thrombosis in children: thrombophilia and clinical outcome. 107
Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis. 107
Short-term exposure to high levels of air pollution as a risk factor for acute isolated pulmonary embolism. 107
New prothrombin mutation (Arg596Trp, Prothrombin Padua 2) associated with venous thromboembolism 105
ABO blood group and the risk of post-thrombotic syndrome 105
Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S 105
Non-invasive risk stratification after HCV-eradication in patients with advanced chronic liver disease 105
Factor IX activity/antigen ratio and the risk of first unprovoked venous thromboembolism. 105
Effects of glycosaminoglycans and protamine chloridrate on platelet aggregation induced by collagen and thrombin. 103
Platelet factor V levels in moderate to severe congenital factor V deficiency. 103
Cerebral sinus venous thrombosis with parenchymal infarcts in a newborn with severe haemophilia A and subdural haematomas. 103
Cell therapy for Parkinson's disease: A translational approach to assess the role of local and systemic immunosuppression 103
Predictors of postoperative bleeding in children undergoing cardiopulmonary bypass: A preliminary Italian study 103
A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis 102
Studies on coagulation incompatibilities for xenotransplantation. 101
Modulating thrombotic diathesis in hereditary thrombophilia and antiphospholipid antibody syndrome: A role for circulating microparticles? 101
The molecular genetics of familial venous thrombosis 101
Clinical and laboratory characteristics of isolated lupus anticoagulants 100
The role of antiphospholipid antibodies toward the protein C/protein S system in venous thromboembolic disease. 99
The biological inertia of coumarin-induced pre-factors (so called PIVKAs) 99
Whole blood rotation thromboelastometry (ROTEM®) profiles in subjects with non-neoplastic portal vein thrombosis. 99
Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth? 99
Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events 99
Factor VIIa-antithrombin complexes in patients with non-neoplastic portal vein thrombosis with and without cirrhosis. 99
Hypercoagulability detected by whole blood thromboelastometry (ROTEM®) and impedance aggregometry (MULTIPLATE®) in obese patients 99
Thromboelastometry guided fibrinogen replacement therapy in cardiac surgery: a retrospective observational study 99
Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference 99
Perioperative coagulation assessment of patients undergoing major elective orthopedic surgery 99
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies 99
Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. 99
Procoagulant activity in children with community acquired pneumonia, pleural effusion and empyema 98
Effects of long-term administration of recombinant human protein C in xenografted primates. 98
The Risk of Cancer Progression in Women With Gynecological Malignancies and Thrombophilic Polymorphisms: A Pilot Case-Control Study. 97
Whole blood coagulation assessment using rotation thrombelastogram thromboelastometry in patients with acute deep vein thrombosis. 97
Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. 95
The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein i antibodies. A comparison with a homemade ELISA method 95
Heterozygous protein-S deficiency: a study of a large kindred. 95
Thrombotic manifestations in plasminogen deficiency and in plasminogen abnormalities. 94
Similar hypercoagulable state and thrombosis risk in type I and type III proteinS-deficient individuals from mixed type I/III families. 94
Origin and levels of circulating microparticles in normal pregnancy: A longitudinal observation in healthy women 94
Characterization of an apparently synonymous F5 mutation causing aberrant splicing and factor V deficiency 94
Evaluation of a procoagulant phospholipid functional assay as a routine test for measuring circulating microparticle activity. 94
Pitfalls of protein C assays in patients with activated protein C resistance 93
Hypercoagulability In Cirrhotic Patients With Hepatocellular Carcinoma (hcc) and Portal Vein Thrombosis (pvt) 93
Naturally occurring Arg-1 to Leu mutation in human protein C (protein C Padua(3)) resulting in an abnormal propeptide processing and in a molecule with discrepant functional activities 93
Alterations in the coagulation profile in renal pig-to-monkey xenotransplantation 92
Whole blood thromboelastometry profiles in women with preeclampsia 92
Guidelines for resuscitation in the delivery room of extremely preterm infants 91
Factor V Leiden and prothrombin gene mutation in inflammatory bowel disease in a Mediterranean area 90
Severe arterial cerebral thrombosis in a patient with protein S deficiency (moderately reduced total and markedly reduced free protein S): a family study. 90
Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis 90
Childhood stroke associated with familial protein S deficiency. 89
Thromboelastometry profiles in patients undergoing thrombolytic therapy for acute ischaemic stroke 89
Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases 89
COVID-19 and Venous Thromboembolism in Intensive Care or Medical Ward 89
Tailored prophylaxis with rFXIII (NovoThirteen ® ) in a young girl with severe FXIII deficiency and previous cephalohaematoma 89
Soluble endothelial protein C receptor (sEPCR) levels and venous thromboembolism in carriers of two dysfunctional protein C variants 88
Clinical and laboratory expression of associated thrombophilic conditions (homozygous/heterozygous factor V Leiden mutation and heterozygous prothrombin variant 20210A) in an Italian family 88
Genetic modulation of the FV(Leiden)/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes. 88
Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct acting antivirals 88
The sudden and unexpected appearance of inhibitors in a previously treated severe haemophilia B patient after the switch to albutrepenonacog alpha 88
Association between ABO blood group and bleeding phenotype in patients with mild rare bleeding disorders 88
The current understanding of trauma-induced coagulopathy (TIC): a focused review on pathophysiology 88
Factor V Leiden is associated with more distal location of deep vein thrombosis of the leg. 87
Hypercoagulability in cirrhotic patients with hepatocellular carcinoma (HCC) and portal vein thrombosis (PVT) 87
Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. 87
Phenotype and genotype expression in pseudohomozygous R2 factor V 86
Obstetric complications and pregnancy-related venous thromboembolism: the effect of low molecular weight heparin on their prevention in carriers of factor V leiden or prothrombin G20210A mutation 86
A new global test for the evaluation of the protein C-protein S system. 86
Factor VIIa-antithrombin complexes in children with ischemic stroke. 86
The relationship between defective heparin cofactor activities and thrombotic phenomena in AT III abnormalities. 86
Totale 10.476
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.878
article - articoli 102.761
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 92
Totale 207.731
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.626 0 0 0 0 0 0 0 0 0 530 1.165 931
2019/20206.465 943 257 55 426 687 495 638 800 846 675 317 326
2020/20215.413 181 424 254 503 522 255 171 521 609 626 589 758
2021/20225.842 181 604 694 402 310 381 249 668 319 155 535 1.344
2022/20234.109 892 389 93 428 719 517 16 280 481 48 189 57
2023/20241.787 105 341 257 223 168 240 165 106 93 89 0 0
Totale 30.330